VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Vanda Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.09+0.06 (+1.49%)
Close on Oct 19, 2026
- Market cap
- $246.33M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.18 (−22.39%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Vanda Pharmaceuticals Inc. grew revenue 6.0% to $215.72M over the twelve months to Jun 30, 2026. Free cash flow was -$143.01M.
Revenue
$215.72M
+6.0% vs. a year earlier
Operating income
-$185.67M
TTM Q2 2026
Free cash flow
-$143.01M
TTM Q2 2026
EPS, diluted
-$4.63
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $246.33M
- P/E ratio
- –
- Price to sales
- 1.14
- Price to book
- 1.12
- Dividend yield
- –
- Free cash flow yield
- -58.06%
Fundamentals
- Revenue
- $215.72M
- Net income
- -$274.85M
- EPS, diluted
- -$4.63
- Free cash flow
- -$143.01M
- Book value per share
- $3.66
- Diluted shares
- 60M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$215.72M+6.0% YoY
Gross profit
$202.22M+5.3% YoY
Operating income
-$185.67M
Net income
-$274.85M
EPS, diluted
-$4.63
Free cash flow
-$143.01M
Reported periodTrailing twelve months